Pemvidutide vs Semaglutide

Overview

Pemvidutide (ALT-801) is Altimmune’s investigational dual GLP-1/glucagon receptor agonist being developed for obesity and MASH (metabolic dysfunction-associated steatohepatitis). Like other dual agonists, pemvidutide adds glucagon activity to GLP-1 effects, potentially offering enhanced liver fat reduction and weight loss.

Mechanism Comparison

Aspect	Pemvidutide	Semaglutide
Target Receptors	GLP-1 + Glucagon	GLP-1 only
Receptor Activity	Dual agonist	Single agonist
GLP-1:Glucagon Ratio	Balanced	N/A
Unique Feature	Liver fat focus	Proven CV benefit

Glucagon’s Role in Pemvidutide

Glucagon receptor activation provides:

• Increased hepatic lipid oxidation
• Enhanced energy expenditure
• Greater liver fat reduction
• Potential MASH benefits beyond weight loss

Evidence Comparison

Aspect	Pemvidutide	Semaglutide
Development Phase	Phase 2	FDA Approved
Human Trials	MOMENTUM, ongoing	Extensive (STEP, SUSTAIN, SELECT)
MASH Data	Phase 2	Limited
CV Outcomes	Not studied	SELECT positive

Clinical Trial Data

Pemvidutide (MOMENTUM Trial - 48 weeks)

Dose	Weight Loss
1.8mg weekly	~10.7%
2.4mg weekly	~15.6%

Semaglutide 2.4mg (STEP 1 - 68 weeks)

Metric	Result
Weight Loss	~14.9%
>=10% Weight Loss	69%
>=15% Weight Loss	51%

Comparison: Similar weight loss magnitude, though different trial designs.

MASH/Liver Effects

Outcome	Pemvidutide	Semaglutide
Liver Fat Reduction	~70% (MRI-PDFF)	~50%
MASH Focus	Primary development	Not primary
Fibrosis Effects	Being studied	Limited data

Glucagon agonism appears to enhance liver fat reduction beyond GLP-1 alone.

Regulatory Status

Aspect	Pemvidutide	Semaglutide
FDA Status	Investigational	Approved
Primary Indication	MASH, Obesity	T2D, Obesity, CV risk
Phase	Phase 2	N/A (marketed)
Developer	Altimmune	Novo Nordisk

Administration

Aspect	Pemvidutide	Semaglutide
Route	Subcutaneous	SC + Oral

Side Effect Profile

Effect	Pemvidutide	Semaglutide
Nausea	Common	Common
Vomiting	Common	Common
Diarrhea	Common	Common
Constipation	Less common	Less common

Typical incretin-class GI effects for both.

Competitive Landscape

Dual GLP-1/Glucagon Agonists

Compound	Developer	Status
Survodutide	Boehringer	Phase 3
Mazdutide	Innovent/Lilly	Phase 3 (China)
Pemvidutide	Altimmune	Phase 2

Pemvidutide is behind survodutide in development.

Key Differences

Factor	Pemvidutide	Semaglutide
Glucagon activity	Yes	No
Liver fat reduction	Enhanced	Moderate
MASH development	Primary	Not primary
Approval status	Investigational	Approved
Company size	Small biotech	Large pharma

Developer Considerations

Factor	Altimmune (Pemvidutide)	Novo Nordisk (Semaglutide)
Resources	Limited	Extensive
Manufacturing	Scaling challenges	Scaled (with shortages)
Commercial capability	Partnership likely	Global infrastructure
Development speed	Resource-constrained	Well-funded

Summary

• Pemvidutide is a dual GLP-1/glucagon agonist with promising liver fat reduction and ~16% weight loss
• Semaglutide is the proven GLP-1 agonist with extensive data, approval, and CV benefit
• Glucagon agonism provides enhanced liver effects relevant for MASH
• Pemvidutide faces competitive pressure from larger players (Boehringer, Lilly)
• MASH indication may be key differentiator for smaller developers

---

This comparison is for educational purposes only. Pemvidutide is investigational. Consult a healthcare provider for treatment decisions.